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1. To date over 800 complete genomes have been sequenced, with many more 
partially complete. Coupled with the large amount of mRNA transcript 
sequence data being produced from expression studies there is now a daunting 
amount of information available to the research scientist. This review will aim 
to examine how this information may be best used, focussing on examples 
from sequences encoding ADME-related proteins in particular.  
2. Through the use of phylogenetic, splice variant and SNP analysis I shall 
examine how insights into not only species-specific responses to drug 
exposure may be gained, but also how best we utilize this information to 
predict both individual human responses and the impact of population variance 
in response. 
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General Introduction 
The ultimate aim of biological sciences has always been to understand how the body 
works, to actually explain what makes humans tick. An extension of this is required 
by the ADME scientist; not only to understand how the body works but, more 
importantly, to be able to predict how it will respond to chemical exposure. In the last 
decade a step-change has occurred in the capacity of man to generate information 
about the biological subsystems of the body, and how these alter in response to 
chemical exposure. This increase in technological ability has resulted in a huge 
amount of data available in silico to the research scientist; the challenge now is how 
to make the most use of this information. 
This review will aim to examine the emergent technologies available for large 
scale information gathering, as well as the databases where such information is stored. 
Whereas public data storage is a central part of open-access research for the scientist, 
perhaps of more import today is the development of tools with which to analyse this 
freely available data, and a selection of these tools will also be covered in this review. 
Public domain storage of sequence information and the development of 
computational tools to examine such a large amount of data are central to our further 
understanding of systems biology. However, six years after the sequencing of the 
human genome how far have we actually come? What insights (if any) have we learnt 
through the mining of these large databases? This review will attempt to address this 
question, or at least some parts of it,  by examining how in silico analysis has aided 
our understanding of human biology, and in particular ADME: First, how the 
sequencing of non-human genomes may increase our knowledge of how the human 
body functions. Second, the discovery of novel genes, which may represent novel 
therapeutic targets, or whose protein products may impact upon ADME processes. 
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Finally, how single nucleotide polymorphism (SNP) analysis may help researchers to 
understand/predict inter-individual variation in response to chemical exposure. 
 
Looking in to the past: What can phylogenetic analysis tell us? 
There are presently fully sequenced genomes from just over 800 different species 
(www.ncbi.nlm.nih.gov/), the majority of which are available through public domain 
repositories such as NCBI, EBI and GenomeNet (based in the USA, Europe and Japan 
respectively).  If one also includes all currently active genome sequencing projects 
then this number increases to over 4500 (Table 1), with approximately one third of 
these being animal species. However, a cursory glance at these will tell you that of 
these 800 only a relatively small number represent species directly applicable to the 
AMDET process (Table 2). 
 
[TABLE 1+2 AROUND HERE] 
 
The impact of the human genome sequence has been obvious and immediate; with 
it we are (theoretically) able to identify every human gene and extrapolate this 
information to functional biology. Indeed, some startling discoveries have been made 
such as the relatively low number of genes (now estimated at 20-25,000; Consortium 
2004), and the overall high level of identity to supposedly very different organisms 
such as the mouse (Lander, et al. 2001, Waterston, et al. 2002). What has not been 
achieved (yet) however is a full understanding of the human biological system and all 
its intricate workings, and for that the other 800+ sequenced genomes have a 
significant role to play. From a homocentric point of view one can imagine that 
humans are at the (current) end of an evolutionary process that began some 3.5 billion 
 5
years ago (Kumar and Hedges 1998). This evolutionary process, culminating in Homo 
sapiens has revolved around the emergence of traits that allow humans to survive in 
our particular environment. Thus, we cannot say that we are the pinnacle of evolution, 
merely the end of this particular branch; other organisms have evolved to suit their 
particular environments and are hence the ‘top’ of their evolutionary tree. Traits that 
are beneficial for survival are kept, whereas those that are non-essential to life may be 
lost or altered through time. Following this argument in reverse it can be argued that 
traits (or genes) maintained in a large number of organisms are important for life in 
general, whereas those that exist in only a single species are important for that 
organism to exist in its particular environment. Through the study of the genomes of 
our evolutionary ancestors it may thus be possible to gain insights into the functioning 
of the human body. In addition, the less complex biological systems exhibited by 
many of these organisms means that gene functions are much better described, and 
hence it is possible to gain insights into human systems biology through the study of 
these ‘simpler’ organisms. 
Genes whose protein products are involved in ADME lend themselves well to this 
type of analysis for a number of reasons. First, the need to respond to external 
chemicals has existed for a long time, thus meaning that these genes are present 
through millions of years of phylogenetic lineage. Second, the requirement to respond 
to a large number of different chemical entities has resulted in relatively large gene 
families: Such large numbers per species are useful in phylogenetic analysis for 
examining differences between evolutionarily close species (e.g. rats and humans). 
Third, the different environments that organisms are exposed to results in different 
pressures upon them, favouring the emergence of traits to cope with these specific 
pressures. By studying how different organisms have evolved to cope with their 
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particular environments we may gain important insights into how humans have 
evolved to cope with ours. 
Perhaps the two best examples of where phylogenetic analysis has yielded insights 
into biological function for ADME-related genes are the cytochrome P450s and their 
controlling ligand-activated transcription factors, the nuclear receptors. 
Cytochrome P450 phylogenetic analysis 
Cytochrome P450 (CYP) enzymes are amongst the most ancient proteins known, with 
gene present in all species examined from archaebacteria to humans (Nelson, et al. 
1996). The reason for the prevalence is simple; CYPs are a fundamental enzyme 
family in the metabolism (both anabolic and catabolic) of the endogenous chemicals 
required for life (Nebert and Gonzalez 1987). Their ability to metabolise xenobiotics 
is to a great extent an acquired secondary characteristic, albeit one central to ADME. 
Indeed, the majority of human CYPs are still concerned with endogenous metabolism, 
with only CYP families 1-3 (representing 18 out of 57 human CYPs) primarily 
concerned with the metabolism of xenobiotics (Werck-Reichhart and Feyereisen 
2000). The number of CYP genes underwent a rapid increase following the 
development of organisms with a gastro-intestinal tract, with increased chemical 
intake through the diet becoming a significant driver in the need to evolve new 
proteins capable of metabolising these chemicals (Nebert and Gonzalez 1987). An 
interesting example of this is how rodents have evolved over 100 individual CYP 
genes, far greater than the 57 found in humans. A cogent argument is that omnivorous 
rodents take in many more chemicals through their diet due to their scavenging 
lifestyle, and hence require more CYPs to protect them from potential toxins. 
The Committee for Standardised Cytochrome P450 nomenclature has accepted the 
unenviable task of bringing all CYP sequence-related research under one roof, and 
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more importantly under one naming system. Sequences are named according to their 
identity, being assigned to families and sub-families at the 70 % and 40 % identity 
levels respectively. Such a nomenclature relies upon the accuracy of gene 
identification, and by inference the accuracy of gene prediction software (Wang, et al. 
2004). Unfortunately, Cytochrome P450 gene sequences do not lend themselves well 
to automated identification; CYP genes sequences are often highly similar, and often 
exist as chromosome clusters of related genes. Such clusters are easily misinterpreted 
by automated gene prediction programs, producing ‘fusion-genes’ from two CYP-
gene sequences within the gene cluster (Nelson 2002, Nelson 2005). For example, in 
human the four CYP3A sub-family members CYP3A4, 5, 7 and 43 are located on 
chromosome 7q21 within a single cluster, demonstrating an average 82 % identity 
(Gibson, et al. 2002). CYP gene prediction is particularly difficult in plant genomes, 
where gene clusters can extend to 10 or more highly related gene sequences (Nelson, 
et al. 2004). To further complicate the situation some CYP genes have evolved 
remarkably short exons, often comprised of only three or four amino acids 
(Doddapaneni, et al. 2005). Such short exons are often excluded by automated gene 
prediction programs, obviously impacting upon any naming system relying upon 
sequence identity, as well as potentially altering the implied biologically functioning 
of the protein products. Thus, it can be seen that whereas there have been huge 
improvements in the gene-hunting software available, for many gene families such as 
the CYPs there is no alternative but painstaking individual annotation by scientists. 
More than anything else this justifies the existence of websites such as the Committee 
for Standardised Cytochrome P450 Nomenclature, preventing duplication of this 
painstaking work, or invalid investigations based upon the erroneous gene sequences 
produced via automated data mining. 
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The many genome sequencing projects underway now make it possible to 
examine CYP evolution among a wide range of organisms, including humans and 
rodents (96 million years divergence), humans and pufferfish (420 million years 
divergence; Nelson 2003) and humans and Arabidopsis (670 million years 
divergence; Nelson, et al. 2004). Through the study of CYPs in a monocot (Oryza 
sativa, Japanese rice) and dicot (Arabidopsis) plant it is apparent that plants have 
many more CYPs than humans, with these species having ~350 and ~250 CYP genes 
respectively. The reason for this large number of CYP genes is not clear, but Nelson 
and colleagues speculate that it may be as a result of the pressures exerted on early 
plants during colonization of land (Nelson, et al. 2004). Of the rice and Arabidopsis 
CYPs approximately two-thirds are shared, having emerged prior to the monocot-
dicot divergence 200 million years ago; however, despite this large overlap in shared 
genes only approximately one fifth of the CYP subfamilies are conserved, with these 
presumably encoding those CYPs involved in reaction fundamental to survival.   
Comparing CYPs from humans and the pufferfish (Takifugu rubripes) produces 
far fewer differences than observed between plants and humans (Nelson 2003). 
Despite over 420 million years of divergence pufferfish and humans share 17 out of 
the 18 CYP families, and within these families gene structures (e.g. intron-exon 
boundaries) are well conserved. Such results suggest that the defining characteristics 
of vertebrate CYPs have been in place for at least 420 million years, with the only 
major divergences seen in those subfamilies, such as CYP2C, which are primarily 
targeted towards the metabolism of xenobiotics (Nelson 2003). The unique family in 
humans compared to pufferfish is CYP39, and this in itself is interesting as the 
emergence of this sub-family provides an alternate pathway for the biosynthesis of 
bile acids: This is a demonstration of the ability of CYPs to produce safety-nets, 
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whereby important metabolic functions exhibit redundancy in an attempt to prevent 
toxicity due to disruption of cellular homeostasis.  
Nuclear receptor phylogenetic analysis 
If the CYP-family members are the engines of Phase I metabolism then the nuclear 
receptors can be envisaged as the drivers; they control the when, where and how 
much for expression of many of the CYP genes as well as a large number of other 
gene families involved in ADME. It is thus logical to apply the same phylogenetic 
analysis to this family of ligand-activated transcription factors as it was to their target 
genes; understanding the evolution and biological functioning of nuclear receptors 
may help researchers further understand the regulation/functioning of their target 
genes. 
Following the complete sequencing of the first three mammalian genomes 
(human, rat and mouse) Zhang and colleagues undertook an examination of the 
nuclear receptor family in these three species, employing a different approach to 
identifying novel related genes (Zhang, et al. 2004). Using the Pfam database 
(http://www.sanger.ac.uk/Software/Pfam/; Bateman, et al. 2004) these latter authors 
identified six structural and functional protein domains specific for the members of 
the nuclear receptor family, and then identified these in the 62 previously annotated 
human, rat or mouse nuclear receptors. Next, the complete genomes of the three 
species were examined for these Pfam domains using GENEWISEDB (Birney and 
Durbin 2000). Finally, alignment to the known nuclear receptor family members was 
then used to complete gene characterization. Using this methodology an additional 82 
complete nuclear receptor genes were identified, along with two decayed aberrant 
genes sequences and ten pseudogenes. Of the 144 complete genes, 47 were present in 
rats, 49 in mice and 48 in humans; in itself an interesting finding when one considers 
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the disparity in murine and human CYP number, archetypal nuclear receptor target 
genes. The ‘missing genes’ in rats are NR1D2 and NR2E3, but their absence may be 
explained by gaps in the rat genome sequence at the places where they would be 
predicted to occur based upon their location in the mouse genome.  
Examination of the rate of nucleotide substitutions within the nuclear receptor 
family, resulting in either synonymous (Ks) or non-synonymous (Ka) amino acid 
substitutions within the translated protein, revealed little species-specific differences, 
suggesting that for most of the nuclear receptors ligands were unlikely to be species-
specific. However, for PXR and CAR Ka/Ks values were 4.0 and 5.6 times greater 
than average respectively, suggesting positive selection for ligands; this is perhaps 
unsurprising considering the role of these two nuclear receptors in regulating the 
body’s ability to respond to external chemicals, exposure to which is often species-
specific due to the different diet compositions of these species. Such information must 
also raise concerns for ADME-testing and species extrapolation; this data confirms 
the observation first made in CYPs, that the very proteins whose responses we wish to 
study/predict are those that evolve the most rapidly and are therefore the most 
problematic to predict for. Increased Ka/Ks rates were also observed for members of 
the NR0B and NR1H sub-families, although the biological causes/consequences of 
this have not yet been elucidated. 
The examination of the nuclear receptor family has resulted in a number of 
important discoveries. First, rapid evolution of members of this family, in particular 
PXR and CAR, demonstrates a strong positive selection, probably driven by the need 
to respond to external stimuli. Indeed, the Chicken Xenobiotic Receptor (CXR) has 
diverged into the Constitutive Androstane Receptor (CAR, NR1I3) and Pregnane X 
Receptor (PXR, NR1I2) in the space of only 310 million years (Handschin, et al. 
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2000). As a result of this divergence, higher vertebrates, including primates, have 
gained a second receptor targeted toward the capture, interpretation and response to 
external stimuli, potentially an important factor in the success of these species in 
surviving on an omnivorous diet. Second, this evolution has resulted in the same sort 
of redundancy seen in the CYP enzymes, where one chemical may be a ligand for 
several receptors (e.g. CAR and PXR) providing a ‘metabolic safety net’ (Xie, et al. 
2000), or where internal control mechanisms (e.g. auto-regulation of PXR expression 
by PXR protein) are present to regulate the biological action of these interactions, thus 
preventing/reducing negative impacts on cellular homeostasis (Aouabdi, et al. 2006). 
Perhaps the most surprising conclusion from the phylogenetic analysis was the 
ancestry of the SHP and DAX1 genes. SHP and DAX1 are the two members of the 
NR0 family of nuclear receptors and are unique in the fact that they do not contain a 
DNA-binding domain (Bavner, et al. 2005). The lack of functional DNA-binding 
capacity within these two proteins was suggestive of ancient nuclear receptors, from 
which the DNA-binding, fully functional family members had evolved (Guo, et al. 
1996). However, this more complete phylogenetic analysis clearly demonstrates that 
these two latter nuclear receptors evolved from the NR2 branch of the phylogenetic 
tree, rather than acting as the root for the entire tree. During, or closely after the 
emergence of these NR0 family members the DNA-binding domain coding sequence 
appear to have been lost, with rapid sequence evolution following. The biological 
consequence of nuclear receptors without DNA-binding capacity is now emerging, 
with both SHP and DAX1 being implicated in the regulation of other nuclear 
receptors via protein:protein interactions (Bavner, et al. 2005, Niakan and McCabe 
2005). The formation of non-DNA binding heterodimers of SHP/DAX1 with other 
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nuclear receptors effectively acts as a sink, removing nuclear receptors from the pool 
available to interact with ligand and/or DNA, regulating their biological effect. 
 
New gene discovery 
Expressed Sequence Tag Analysis 
The advent of high throughput sequence analysis has had two major benefits. As 
discussed in the previous section, the first of these is the production of complete 
genome sequences for a large number of organisms, allowing phylogenetic analysis of 
gene families, providing further insights into their biological roles. The second major 
benefit is a large increase in the number of expressed sequences available in 
databases. These sequences are often multiple repeat sequencing reads of known 
genes/transcripts, which can be used to identify sequence variation, as will be 
discussed in the next section. However, a large number of these sequences are 
unassigned to any particular gene/transcript and hence may represent ‘novel’ 
sequences; herein I will discuss how these potentially novel sequences can be further 
examined.  
Entire sections of sequence repositories are now devoted to expressed sequence 
tags (ESTs); those sequences are derived from mRNA and which should therefore 
result in a protein product, but for which no protein product or biological function has 
been assigned. It is from this latter pool that the exciting possibility of novel gene 
identification emerges. Before classifying any EST as a product of a ‘novel gene’ it is 
important to note that the majority of ESTs merely represent unassigned transcripts 
and not novel transcripts. Due to technical considerations in transcript 
isolation/processing and the use of high throughput single-read sequencing, much of 
the transcript sequence deposited in databases is not full length and biased towards the 
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3’ terminus. Given that the majority of eukaryotic genes produce transcripts with 
untranslated regions (UTRs) at either extremity, and that the average length of a 3’ 
UTR is 826 bp for humans (Wren, et al. 2000) and 
http://innovation.swmed.edu/research/informatics/res_inf_pom.html), it is perhaps not 
surprising that the majority of ESTs contain mainly 3’ UTR sequences. As UTRs are 
in general not as well conserved as the coding sequence within a transcript (Wren, et 
al. 2000) identification of any transcript from this sequence may be problematic as 
identification via orthologues may be inaccurate, particularly for transcripts from 
large gene families, such as those associated with ADME. Hence, ESTs often merely 
represent 3’ sequences of transcripts that have not been married to their known genes, 
and this can be achieved with relative ease using simple database searching. However, 
a number of ESTs do not map to known genes, nor translate to proteins of known 
function; these represent transcripts from completely novel genes, and are of 
particular interest both in understanding the potential biological effects of chemicals, 
but also for the identification of potential novel therapeutic targets for the treatment of 
disease. 
Target Gene Identification 
An important step in understanding/predicting how the body responds to chemical 
exposure is the characterisation of what molecular events occur immediately 
following exposure. Such events may be classed as direct (e.g. binding of a nuclear 
receptor to its target gene) or indirect (e.g. expression of other genes as a result of the 
direct actions of the chemical), and it is important to separate these two if we are to 
fully understand the molecular responses to chemical stimulation. To understand the 
chronology of response, and hence the mode of action of chemicals it is important to 
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identify the primary gene targets, with these later being associated with (secondary) 
biological responses.  
An example of such an approach is provided by Horie-Inoue and colleagues, who 
mined the human genome sequence to identify potential binding sites for nuclear 
receptors involved in hormone homeostasis/response (Horie-Inoue, et al. 2006). The 
androgen receptor, glucocorticoid receptor, progesterone receptor and 
mineralocorticoid receptor all bind to an IR3 response element comprised of two 
inverted AGAACA half-sites, separated by three nucleotides. Genome wide scanning 
for this sequence identified 565 exact matches for this element, and of these 26 were 
within 10 Kb of the known transcription start sites for annotated human genes. 
Chromosome immunoprecipitation (ChIP) was then used to identify which  nuclear 
receptors (if any) bound to these sites, revealing 14/26 to be active. This data shows 
the potential and limitations of in silico screening; whereas such data mining 
identified 565 potential binding sites, only 5% were close to known genes and of 
these only one-half were shown to be bound by a nuclear receptor. Thus, while such 
techniques can be seen to generate a lot of potential clues, they do not provide the 
answers – for that wet-lab experiments are a necessity.  
It should also be noted that this type of analysis concentrates on perfect matches to 
the consensus binding site, and will almost certainly miss some functional binding 
sites as nuclear receptors have been clearly demonstrated to bind to sequences 
divergent from their consensus binding site (Song, et al. 2004, Xie, et al. 2000). This 
is highlighted by the recent work of Steketee and colleagues who, rather than search  
for one perfect ‘consensus’ element within a large amount of DNA, searched for 
many near-perfect elements within a restricted region of DNA (Steketee, et al. 2004). 
Using this approach these latter authors identified a non-perfect HRE within the first 
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intron of the specifically androgen-regulated gene (SARG), and went on to show that 
this site was functional via ChIP.  
Hence, it can be seen that a combination of the two previous methods is 
recommended to provide the most complete coverage for identifying putative 
transcription factor binding sites – an arduous task given the complexity of the human 
genome. A potential solution for this problem is the use of phylogenetic 
fingerprinting. Through the use of programs such as rVISTA (Loots and Ovcharenko 
2004, Loots, et al. 2002) and PipMaker (Schwartz, et al. 2000) it is possible to scan 
genome sequences for areas of conservation across species (Pennacchio and Rubin 
2003). Those regions that show highest conservation usually correspond to genes, 
with the next most highly conserved regions often representing regulatory elements. 
Using such an approach Ozyildirim and colleagues recently examined lacrimal gland 
transcriptomes to identify ‘lacrimal-specific’ transcripts, plus the regulatory elements 
putatively involved in their expression (Ozyildirim, et al. 2005). They were able to 
identify a number of ‘lacrimal-specific’ transcripts but showed that conservation of 
the expression and regulation of these specific transcripts between mouse and human 
was poor; questioning the relevance of currently used murine models of human dry 
eye syndromes. 
Biological function identification 
Another benefit from the large sequence repositories is that there is now a large 
amount of data available for transcript expression levels in different tissues and under 
different conditions. With such information it should be possible to identify 
differences between, for example, normal and diseased tissue (Mandel, et al. 2003, 
Mariadason, et al. 2002) or before and after exposure to a chemical (Natsoulis, et al. 
2005, Rogler, et al. 2004). This would allow the identification of the expression 
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changes elicited by a stimulus, and through modelling of the pathways affected by 
these changes insights into the molecular mechanisms of response can be gained. 
Massively parallel signature sequencing (MPSS) is a technique for generating 
large numbers of very short sequences very rapidly (Brenner, et al. 2000). These can 
then be identified through mining of sequence databases to identify longer sequences 
for which genes/protein products have been assigned, and the number of tags present 
for each signal provides a measure of the expression level. The throughput of MPSS 
means that all transcripts within a given cell (>200,000) can be sampled very rapidly, 
meaning that the complete cataloguing of gene expression within cell types/conditions 
is now possible (Jongeneel, et al. 2005). Chen and colleagues used such an approach 
to first identify 1,056 transcripts predominantly expressed in human testis, and then 
compared the expression of these genes in normal tissue and testis cell lines. Using 
this approach they were able to identify 20 cancer/testis antigen genes, whose 
expression is linked to the hypomethylation that occurs during cell transformation 
(Feinberg, et al. 2002), including a previously unidentified gene family. Such genes 
offer exciting potential therapeutic targets for the development of antibody-based anti-
cancer agents.  
 
SNPs and Splicing: Producing alternate transcripts 
As previously discussed, the rapid increase in the size of sequence databases is due to 
two main driving forces, the sequencing of novel genes/transcripts/genomes from 
disparate species and the repeated sequencing of these targets. The repeat sequencing 
of already ‘known’ sequences is important for two functions: First, it confirms the 
accuracy of a sequencing project, analogous to the requirement to carry out a wet-lab 
experiment at least twice to confirm the validity/robustness of conclusions, and 
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second, it reveals any variation seen within that sequence that is not due to 
experimental/technical error but a true variation seen within the general population. 
This variation may be due to alternative splicing of identical pre-mRNA transcripts, 
or due to variations within the genome itself; both of these scenarios will be discussed 
in the following sections, along with their potential implications for ADME. 
Splice variants of ADME-related genes 
Following the discovery that the human genome contains only approximately 20,000 
genes came the realisation that added complexity must be factored in to achieve the 
total number of observed proteins in humans, estimated at an order of magnitude 
higher. A large amount of this variation can be accounted for by the presence of post-
translational modifications such as phosphorylation, which occur to most proteins. 
However,  it is becoming increasingly clear that at least some of this increase in 
complexity is achieved through the use of alternative splicing, where different  exons 
are spliced  together from the nascent pre-mRNA to form the mature mRNA, 
translation of which produces a protein product with the inclusion/removal of 
different amino acid cassettes (Lareau, et al. 2004). Indeed, it has been estimated that 
more than half of all human genes are capable of producing alternative splice variants 
(Hanke, et al. 1999). Such splice variants may have a number of roles; for example 
the tumour necrosis factor receptor gene (TNFR) gives rise to at least ten different 
splice variants, which may affect factors such as sub-cellular localisation of the 
receptor (Xing, et al. 2003) or cellular predisposition to apoptosis (Screaton, et al. 
1997). A number of specialist websites have now been developed to provide central 
repositories for alternate splice variants of genes, some of which are given in Table 3. 
 
[TABLE 3 AROUND HERE] 
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Alternative splicing of ADME-related genes is a common phenomenon, with 
examples existing at the level of drug transporters, nuclear receptors and enzymes. 
This review will concentrate on splice variants within ADME-related enzymes as 
examples of both the prediction and biological consequences of alternative splicing. 
N-acetyltransferases are widely expressed enzymes important in the conjugation of 
amino and hydroxyl amino groups with acetate, and are responsible for the 
metabolism of a number of xenobiotics, including the activation of arylamine and 
heterocyclic amine procarcinogens (Gooderham, et al. 2001). In humans, two N-
acetlytransferase enzymes are present, NAT1 and NAT2, and recent work by Butcher 
et al described the genomic organization of the former of these genes, and identifies a 
number of splice variants (Butcher, et al. 2005). The NAT1 gene is comprised of nine 
exons, but, unusually, the protein coding region of NAT1 is contained within just a 
single exon, with the remaining eight coding for the 5’ untranslated region (UTR). 
Examination of the NCBI EST database identified these non-coding exons and 
suggested that at least three alternative promoters were involved in the production of 
nine separate splice variants from this gene. As the splice variants alter the non-
coding region of the transcript they do not produce proteins with different activities 
but rather have different translation efficiencies. Butcher et al suggested that the 
differential expression of these splice variants throughout the body may go some way 
to explaining the different activity of NAT1 in different organs of the body. 
An interesting form of alternative splicing seen in a number of ADME-related 
genes is the use of alternative promoters. Here, transcription may begin at a number of 
alternate first exons within a gene, presumably driven via alternative 
biological/xenobiotic stimuli. The resultant pre-mRNA will contain the requisite 
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number of conserved exons plus at least one alternate first exon(s): The mature 
mRNA is then generated through the splicing out of any extra first exons. Examples 
of ADME-related genes for which alternative promoters/first exons play an important 
role in their biological functioning are the UDP-glucoronosyltransferase (UGT1A) 
gene (Tukey and Strassburg 2000) and the N-acetyltransferase 1 gene (Butcher, et al. 
2005). These two examples demonstrate the different biological affects that 
alternative splicing may cause: In the UGT1A gene, splice variants result in proteins 
with significantly different catalytic activities, whereas NAT1 splice variants result in 
different levels of protein expression. The UGT1A gene is of particular interest since 
the protein products generated from four common exons and one, variable, first exon 
are sufficiently different to be termed separate proteins, forming the members of the 
UGT1A-family (Tukey and Strassburg 2000). This is thus an example of how 
alternative splicing can considerably alter the functionality of a protein product, to the 
point where it can be considered a separate entity rather than just a variant. 
Alternate splicing shows the remarkable flexibility of genomic DNA, in that the 
derivation of protein products from static nucleotide sequences can be manipulated to 
increase the complexity of the biological system. Not only is this a very elegant 
method for increasing the ability of a system to change in response to external 
situations, be they developmental stage of chemical exposure, but it also allows the 
maximal variation in protein products to be formed with the minimum changes in 
genomic DNA: Thus, alternative splicing represents a very elegant method for 
biological systems to respond to the World in which it lives. 
 
DNA variation in ADME-related genes 
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Alternative splicing may be seen as a consistent form of variation (if such a thing 
exists!) in that it allows all members of a species to produce alternate transcripts, and 
therefore protein products from a single gene, under different biological conditions. In 
contrast, genetic polymorphisms are defined as variation in genome sequences within 
a population, with not all members of that species having the same sequence. These 
features may be combined, with a polymorphism creating splice variants through the 
addition/removal of splice donor/acceptor sites. For example, expression of CYP3A5 
in humans is varied, with only approximately 25% of American Caucasians 
expressing a functional protein (Gibson, et al. 2002). This variation is, at least in part, 
controlled by a polymorphism that allows the introduction of mini-exons into the 
mature mRNA; as these mini-exons contain stop codons the resultant splice variant 
produces a truncated protein that is non-functional (Kuehl, et al. 2001).  
Polymorphisms are a likely source for the well known variation in predisposition 
to disease, and as such much study has been undertaken on examining associations 
between genotype status and predisposition to disease. However, due to a large 
number of factors (population size/source screened, environmental considerations etc) 
many of these studies have failed to show convincing, or reproducible, associations. 
Perhaps the most convincing association to date between a DME and disease 
predisposition is  CYP19 and hyperandrogenism. In comparison to the relatively 
sparse evidence for associations between DME status and disease predisposition, 
much evidence exists for the role of DME status and variation in response to 
therapeutic agents (Table 4 for examples), and this is hence an important research 
target, particularly given the increasingly global market for drugs. The ability to 
predict the efficacy, or potential adverse effects, caused by drugs when given to 
individuals from different genetic backgrounds would be of great benefit, perhaps 
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even heading towards the holy grail of personalised medicine (Vizirianakis 2004). 
However, before such a goal can be reached not only must the sources of genetic 
variation be identified, but their effect on ADME established. 
 
[TABLE 4 AROUND HERE] 
 
As can be seen from Table 4 even a cursory search of PubMed will reveal a host 
of SNPs associated with altered response to therapeutic agents, resulting in 
loss/reduced efficacy or an increased risk of adverse effects. However, such 
information is not particularly accessible, with the search term largely determining the 
information retrieved. To allow more efficient identification of SNPs and their 
biological function a number of specialized websites have been developed such as 
HGVBase (http://hgvbase.cgb.ki.se/; (Fredman, et al. 2002), dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/; (Sherry, et al. 1999), SNP Consortium 
(http://snp.cshl.org/; (Thorisson and Stein 2003) and HapMap 
(http://www.hapmap.org; (Consortium 2003), which are fully searchable curated 
databases of SNPs. Perhaps the most ambitious of these is HapMap, which aims to 
produce a freely available resource of the frequency and associations between in 
excess of one million variants from population deriving from Africa, Asia and 
Europe; the first phase of this project was recently completed, with 269 DNA samples 
from diverse ethnic backgrounds analyzed for these SNPs (Consortium 2005). In 
addition to these more specialized databases, general databases such as Gene and 
OMIM (both at http://www.ncbi.nlm.nih.gov/), Ensembl (http://www.ensembl.org; 
(Birney, et al. 2004) ) and GeneCards (http://bioinformatics.weizmann.ac.il/cards/) 
contain much useful information on a large number of genes, including 
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common/biologically important polymorphisms, with links to relevant literature; as 
such they should be the first stop for any researcher wishing to assess the potential 
impact of polymorphisms on their pet gene. In relation to ADME-related genes it is 
also worth noting that for CYPs the CYP alleles nomenclature website 
(http://www.imm.ki.se/CYPalleles/) includes details of polymorphisms present within 
the CYP family of genes, along with biological significance, prevalence and related 
literature, although this information is limited to human alleles. 
 
Summary 
The emergence of high throughput sequencing has resulted in a vast increase in the 
information available to researchers in their quest to understand human biology. 
Genome sequencing projects provide information on where we have come from, with 
phylogenetic analysis helping scientists to examine the way humans have evolved to 
cope with their biological needs. Large scale sequencing projects have also revealed 
the large numbers of splice variants used by biological organisms to further increase 
the complexity of their protein pool, allowing humans to respond to variations in their 
present environments. Finally, SNP analysis may give some hints as to where we are 
going, showing genetic variations that are fixed within the population, and their 
effects on an individual’s disease predisposition or response to therapeutic agents. 
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Group Number of Sequencing Projects 
Bacteria 472 
Fungi  508 
Plants 1740 
Lower Eukaryotes 203 
Animals 1581 
TOTAL 4504 
 
Table 1: Current genome sequencing projects 
(Data sourced from NCBI March 2006)
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Order Species Genome Status Reference 
Primates Human Complete. 
Build 35.1 
(Lander, et al. 2001) 
Primates Marmoset In Progress N/A 
Carnivora Dog Complete 
Build 2.1 
(Lindblad-Toh, et al. 2005) 
Lagomorpha Rabbit Microsatellite map (Chantry-Darmon, et al. 2005) 
Rodentia Rat Complete. 
Build 3.1 
(Gibbs, et al. 2004) 
Rodentia Mouse Complete. 
Build 35.1 
(Waterston, et al. 2002) 
Rodentia Hamster Not Started N/A 
 
Table 2: Status of whole genome sequencing projects in ADME-relevant 
mammalian species.
 Database URL Description Reference 
Alternative Splicing 
Database (ASDB) 
http://www.ebi.ac.uk/asd/ Splice variants from annotated genes for human (Thanaraj, et al. 
2004) 
Alternative Splicing 
Annotation Project  
http://bioinfo.mbi.ucla.edu/ASAP/ EST based splice variant prediction with tissue 
information 
(Lee, et al. 2003) 
ProSplicer http://prosplicer.mbc.nctu.edu.tw/ Putative alternative splice variant database for human (Huang, et al. 2003) 
SpliceDB http://www.softberry.com/berry.phtml Canonical and non-canonical splice sites in mammals (Burset, et al. 2001) 
 
 
Table 3: Alternative Splice Variant Databases
 Gene with 
SNPs 
Disease State Reference 
CYP19 Hyperandrogenism (Petry, et al. 2005) 
CYP2E1 Head/neck squamous cell cancer (Neuhaus, et al. 2004) 
CYP2J2 Coronary Heart Disease (Spiecker, et al. 2004) 
CYP1A1  Prostate Cancer (Murata, et al. 2001) 
CYP3A4 Prostate Cancer (Rebbeck 1999) 
GSTM1 Colorectal cancer (Gawronska-Szklarz, et al. 1999) 
GSTT1 Colorectal cancer (Zhang, et al. 1999) 
Serotonin 
Transporter 
Affective Disorder (Collier, et al. 1996) 
ABCA1 Coronary heart disease (Frikke-Schmidt, et al. 2004) 
 
Table 4: Human SNPs associated with an increased predisposition to disease 
states 
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Gene with 
SNP 
Drug Effected  Reference 
CYP1A2 Caffeine (Sachse, et al. 1999) 
CYP2C9 Warfarin (Kirchheiner and Brockmoller 2005) 
CY2C19 Omeprazole (Furuta, et al. 2005) 
CYP2D6 Psychotropic Drugs (Bertilsson, et al. 2002) 
CYP3A5 Tacrolimus (Dai, et al. 2006) 
NAT2 Isoniazid (Donald, et al. 2004) 
TMPT Azothioprine (Jun, et al. 2005) 
UGT1A1 Irinotecan (Ando, et al. 2005) 
MDR1 Nelfinavir (Saitoh, et al. 2005) 
OATP2 Pravastatin, Repaglinide (Niemi, et al. 2005, Niemi, et al. 2004) 
PXR Rifampicn and Paclitaxel (Lim, et al. 2005) 
HLA B Abacavir (Hughes, et al. 2004) 
β-tubulin Taxol/Epothilones (Wang, et al. 2005) 
 
Table 4: Human SNPs associated with altered response to therapeutic agents 
